Evidence map›Paper›PMID 40282336›Full record

ReviewGenes2025

The Bright Future of mRNA as a Therapeutic Molecule.

Dora Emma Vélez, Blanca Licia Torres, Greco Hernández

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dora Emma VélezmRNA and Cancer Laboratory, Unit of Biomedical Research on Cancer, Instituo Nacional de Cancerología (National Institute of Cancer, INCan), Mexico City 14080, Mexico.ORCID 0000-0003-3517-2155
Blanca Licia TorresmRNA and Cancer Laboratory, Unit of Biomedical Research on Cancer, Instituo Nacional de Cancerología (National Institute of Cancer, INCan), Mexico City 14080, Mexico.ORCID 0009-0006-2669-4364
Greco HernándezmRNA and Cancer Laboratory, Unit of Biomedical Research on Cancer, Instituo Nacional de Cancerología (National Institute of Cancer, INCan), Mexico City 14080, Mexico.ORCID 0000-0002-5318-4443

Funding

CONHACyT PhD FellowshipConsejo Nacional de Humanidades, Ciencia y Tecnología (CONHACyT) Program Estancias posdoctorales por México para la Formación y Consolidación de las y los Investigadores por México, 2022.Instituto Nacional de Cancerología Intramural funding program
6 · The paper itself

Abstract

The rapid success of messenger (m) RNA vaccines against COVID-19 has pushed the mRNA to the forefront of drug research. The promise of mRNA-based therapeutics and vaccines in other areas is not new but is now emerging stronger. We review basic concepts, key historical aspects, and recent research on mRNA as a therapeutic molecule to fight infectious diseases and cancer. We also show a current patent perspective of this field. Altogether, we describe that the technology of mRNA as a therapeutic molecule is a rapidly moving field aiming for a bright future.

Indexed as

RNA, MessengerAnimalsCOVID-19COVID-19 Drug TreatmentCOVID-19 VaccinesHumansNeoplasmsSARS-CoV-2COVID-19 VaccinesRNA, Messengercancerdelivery systemsinfectious diseasesmRNAtherapeutic mRNA

Identifiers

PMID40282336
PMCPMC12027115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.